Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders |
Rennova Health, Inc. (RNVA)
|
Add to portfolio |
|
|
Price: |
$0.00
| | Metrics |
OS: |
29.9
|
B
| |
|
|
Market cap: |
$2.99
|
M
| |
|
|
Net debt:
|
$733.7
|
k
| |
|
|
EV:
|
$3.73
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 13.0 | 3.2 | 7.2 | 16.0 | 14.5 | 3.1 | 4.6 | 27.7 |
Revenue growth | 304.4% | -55.2% | -55.0% | 9.9% | 371.1% | -32.6% | -83.5% | -64.1% |
Cost of goods sold | 0.0 | 5.3 | 11.8 | 14.8 | 11.5 | 0.9 | 1.2 | 9.3 |
Gross profit | 13.0 | -2.1 | -4.6 | 1.1 | 3.0 | 2.1 | 3.3 | 18.4 |
Gross margin | 100.0% | -64.2% | -63.7% | 7.1% | 20.9% | 69.3% | 72.8% | 66.3% |
Sales and marketing | | | | | | 0.7 | 1.8 | 3.8 |
Research and development | | | | | | | | |
General and administrative | 7.2 | 7.5 | 11.7 | 16.7 | 14.8 | 15.8 | 17.3 | 27.3 |
EBIT | -4.1 | -10.2 | -16.9 | -16.3 | -13.1 | -16.1 | -21.6 | -25.3 |
EBIT margin | -31.4% | -317.0% | -235.3% | -102.2% | -89.7% | -520.6% | -470.8% | -91.3% |
Pre-tax income | -3.6 | -5.1 | -19.0 | -47.3 | -12.8 | -49.9 | -23.4 | -45.0 |
Income taxes | -0.3 | 0.2 | -1.3 | 0.8 | 0.8 | 1.0 | -0.8 | -9.0 |
Tax rate | 8.7% | | 6.9% | | | | 3.3% | 20.1% |
Earnings from continuing ops | -3.3 | -523.1 | -280.9 | -171.1 | -245.4 | -108.5 | -32.6 | -36.0 |
Earnings from discontinued ops | | 22.2 | -0.7 | -0.8 | -0.4 | | | |
Net income | -3.3 | -500.9 | -281.6 | -171.9 | -245.9 | -108.5 | -32.6 | -36.0 |
Net margin | -25.1% | -15536.2% | -3911.0% | -1075.2% | -1690.0% | -3514.6% | -711.5% | -129.7% |
|
Diluted EPS | | ($953.82) | ($280,898,425.00) | ($0.03) | ($24.49) | ($23,513.77) | ($452.58) | ($86.55) |
Shares outstanding (diluted) | | 0.5 | 0.0 | 5,585.8 | 10.0 | 0.0 | 0.1 | 0.4 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|